The MUC 1 antigen is a membrane-anchored, mucin-type glycoprotein present in malignant and normal epithelial cells of certain organs (ie, breast, lung, ovary, pancreas, and colon)1. The apoprotein of the MUC 1 mucin contains a transmembrane domain, a cytoplasmic domain, and an extracellular carbohydrate-rich domain. The extracellular domain is characterized by polymorphism with respect to the number of a 20 amino acid tandem repeat (VNTR polymorphism). The CA15-3 EIA is based on two mouse monoclonal antibodies, Ma695 as catcher antibody recognizing a sialylated carbohydrate epitope expressed on the MUC 1 antigen and Ma552 as tracer antibody targeting the PDTRPAPG region of the protein core2-5.The MUC 1 breast cancer mucin (CA15-3 antigen) is secreted from tumor cells and is a well-established serological marker for monitoring the clinical course of breast cancer patients6.
Bon, G., Kenemans, P., Yedema, C.A., vanKamp, G.J., Nijman, H.W., and Hilgers, J. (1990) Clinical relevance of the tumor marker CA15.3 in the management of cancer patients in “From Clone to Clinic” p. 111-122, Crommelin and Schellekens (eds.) Kluwer Academic Publishers.
Nilsson O., Karlsson B., Lindholm L., Pettersson A. (1994) Development of assays for determination of MUC 1 breast cancer antigen, 7th Symposium on Tumor Markers, Hamburg 1993, R Klapdor (ed) Current Tumor Diagnostics: Applications, Clinical Relevance, Research, Trends. W. Zuckswerdt Verlag München, 1994.
Bäckström D., Nilsson O., Price MR., Lindholm L., Hansson GC. Discrimination of MUC1 mucins from other Sialyl-Lea-carrying glycoproteins by colon carcinoma cells using a novel monoclonal antibody. Cancer Res., 53, 755, 1993.
Blockzjil A, Nilsson K, and Nilsson O. (1998) Epitope characterization of MUC1 antibodies. Tumor Biology 19 suppl. 1:46-56.
Price M.R. et al., (1998) Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin Tumor. Biology 19 suppl. 1:1-20.
Fleisher M. et al. (2002) Practice guidelines and recommendations for use of tumor markers in the clinic. National Academy of Clinical Biochemistry 15: 26-29.
CanAg CA15-3 EIA
For 96 determinations
Please contact your local Fujirebio representative for the availability of this product in your country.
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.